|
ENAH expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.47210021950173E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.85619999768261E-09 |
| Normal-vs-Stage2 |
2.422800E-03 |
| Normal-vs-Stage3 |
2.68469999997745E-06 |
| Normal-vs-Stage4 |
3.55380000000016E-05 |
| Stage1-vs-Stage2 |
8.988800E-01 |
| Stage1-vs-Stage3 |
4.172800E-01 |
| Stage1-vs-Stage4 |
7.776200E-02 |
| Stage2-vs-Stage3 |
5.294800E-01 |
| Stage2-vs-Stage4 |
1.270770E-01 |
| Stage3-vs-Stage4 |
2.604800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.43850487077657E-11 |
| Normal-vs-AfricanAmerican |
2.143100E-03 |
| Normal-vs-Asian |
6.097500E-03 |
| Caucasian-vs-AfricanAmerican |
8.863000E-01 |
| Caucasian-vs-Asian |
3.190800E-01 |
| AfricanAmerican-vs-Asian |
4.160400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.69829999951965E-07 |
| Normal-vs-Female |
1.24209975638223E-10 |
| Male-vs-Female |
9.286600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.0033999710617E-09 |
| Normal-vs-Age(41-60Yrs) |
3.26070000000733E-07 |
| Normal-vs-Age(61-80Yrs) |
1.93954999999635E-05 |
| Normal-vs-Age(81-100Yrs) |
1.208820E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.586800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.575200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.102000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.441440E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.233600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.596600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.576400E-01 |
| Classical-VS-Follicular |
4.14349999999786E-06 |
| Classical-VS-Other |
3.035400E-01 |
| Classical-VS-Normal |
1.88515869581352E-13 |
| Tall-VS-Follicular |
2.794100E-02 |
| Tall-VS-Other |
1.221770E-01 |
| Tall-VS-Normal |
2.921700E-03 |
| Follicular-VS-Other |
7.689200E-01 |
| Follicular-VS-Normal |
3.190100E-02 |
| Other-VS-Normal |
9.928500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.66840000004331E-06 |
| Normal-vs-N1 |
6.647700E-04 |
| N0-vs-N1 |
2.138800E-01 |
|
|
